Blood and Bone Marrow Transplant Program
The Johns Hopkins Pediatric Bone Marrow Transplant (BMT) Program is a leader in the use of haploidentical donors and the delivery of novel immune therapies for difficult-to-treat cancers, placing the BMT program at the cutting edge of cancer treatment.
Physician-scientists within pediatric blood and marrow transplantation are both devoted clinicians and researchers who strive to maximize efficacy and decrease toxicity of BMT. Our experts are working on projects in the following areas:
- Decreasing regimen-related toxicities and graft-versus-host disease (GVHD)
- Overcoming traditional limitations associated with blood stem cell donor availability and optimizing the selection of the best possible available donor.
- Developing strategies for post-transplant immunotherapy to prevent and/or treat relapse
- Understanding the scope and pace of immune recovery after using haploidentical donors and post-BMT cyclophosphamide
- Novel BMT approaches to ultra-high risk (refractory or relapsed) solid tumors
- Harnessing immune-modulatory and regenerative capacity of non-blood stem cells to reduce the development and severity of post-transplant complications like graft-versus-host disease (GVHD)